- Home
- TNYA vs MDXH Comparison
TNYA vs MDXH Comparison
Compare TNYA & MDXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TNYA
- MDXH
- Stock Information
- Founded
- TNYA 2016
- MDXH 2003
- Country
- TNYA United States
- MDXH Belgium
- Employees
- TNYA N/A
- MDXH N/A
- Industry
- TNYA Medicinal Chemicals and Botanical Products
- MDXH
- Sector
- TNYA Health Care
- MDXH
- Exchange
- TNYA Nasdaq
- MDXH Nasdaq
- Market Cap
- TNYA 73.8M
- MDXH 84.6M
- IPO Year
- TNYA 2021
- MDXH 2021
- Fundamental
- Price
- TNYA $0.63
- MDXH $2.30
- Analyst Decision
- TNYA Strong Buy
- MDXH Buy
- Analyst Count
- TNYA 5
- MDXH 1
- Target Price
- TNYA $8.60
- MDXH $6.00
- AVG Volume (30 Days)
- TNYA 3.0M
- MDXH 70.5K
- Earning Date
- TNYA 08-07-2025
- MDXH 08-20-2025
- Dividend Yield
- TNYA N/A
- MDXH N/A
- EPS Growth
- TNYA N/A
- MDXH N/A
- EPS
- TNYA N/A
- MDXH N/A
- Revenue
- TNYA N/A
- MDXH $94,507,000.00
- Revenue This Year
- TNYA N/A
- MDXH $23.51
- Revenue Next Year
- TNYA N/A
- MDXH $17.68
- P/E Ratio
- TNYA N/A
- MDXH N/A
- Revenue Growth
- TNYA N/A
- MDXH 25.46
- 52 Week Low
- TNYA $0.36
- MDXH $1.35
- 52 Week High
- TNYA $4.06
- MDXH $3.50
- Technical
- Relative Strength Index (RSI)
- TNYA 53.87
- MDXH 58.21
- Support Level
- TNYA $0.54
- MDXH $1.90
- Resistance Level
- TNYA $0.70
- MDXH $2.21
- Average True Range (ATR)
- TNYA 0.06
- MDXH 0.12
- MACD
- TNYA 0.00
- MDXH 0.00
- Stochastic Oscillator
- TNYA 34.57
- MDXH 82.35
About TNYA Tenaya Therapeutics Inc.
Tenaya Therapeutics Inc is a preclinical stage biotechnology company focused on discovering, developing, and delivering curative therapies that address the underlying drivers of heart disease. It is advancing product candidates from three product platforms: gene therapy, cellular regeneration and precision medicine.
About MDXH MDxHealth SA
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.